NASDAQ · Biotechnology

PPCB (PPCB) Stock

$1.01 -2.88% NASDAQ: PPCB Healthcare

Valuation

MetricValue
Price$1.01
Market Cap$883115
P/E Ratio0.00
P/B Ratio0.11
P/S Ratio47.73
EPS (TTM)$-371.25
52-Week High$270.25
52-Week Low$1.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-421.43%
ROA-295.00%
ROCE-407.14%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.16
Current Ratio1.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-2.0M$-2.0M$-2.0M$-57.0M
Net Profit$-2.0M$-3.0M$-3.0M$-2.0M$-59.0M
EPS$-20000.00$-27986891.75$-781709.75$-30000.00$-371.25
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$0$0$0$20.0M
Total Liabilities$3.0M$3.0M$3.0M$4.0M$6.0M
Cash$0$0$0$0$0
Borrowings$1.0M$1.0M$1.0M$1.0M$2.0M

Latest News

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal GlobeNewswire · Jul 21, 2026 Propanc Biopharma Signs MoU With Avance Clinical to Jointly Undertake Advanced Solid Tumors Study MT Newswires · Jul 7, 2026 Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd GlobeNewswire · Jul 7, 2026 Propanc Biopharma Launches $5 Million Stock Buyback Plan; Shares Rise MT Newswires · Jul 2, 2026 Propanc Biopharma Initiates $5.0 Million Share Repurchase Program GlobeNewswire · Jul 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-1.0M$-1.0M$-1.0M$0
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$1.0M$0$0$0
Net Cash Flow$0$0$0$0$0
Free Cash Flow$-1.0M$-1.0M$-1.0M$-1.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-267.28%
Quick Ratio2.37
Interest Coverage-57.00
Return 1Y-98.67%
Return 3Y-65.47%
Return 5Y-99.93%

Ownership

Insiders Held45.13%
Institutions Held0.81%
Institutions Float Held1.48%
Institutional HolderSharesReport Date
UBS Group AG7,3052026-03-31
Jane Street Group, LLC5,7292026-03-31
Marex Group Plc2,7092026-03-31
Virtu Financial LLC1,6302026-03-31
Sassicaia Capital Advisers, LLC6402026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLCSCell Source, Inc. $0.80 -6.98% -8.00 $36.03M 0.00%
GLABFGemina Laboratories Ltd. $0.05 +0.00% -1.54 $3.83M 0.00%
HOOKHOOKIPA Pharma Inc. $1.15 +0.00% -0.71 $14.40M 0.00%
IMUCEOM Pharmaceuticals Holdings, Inc. $0.25 +90.77% -16.32 $31.37M 0.00%
PRVCFPreveCeutical Medical Inc. $0.01 +12.00% -5.00 $8.37M 0.00%

About PPCB

PPCB is led by CEO James Nathanielsz, employs 1 people, headquartered in AU, publicly traded since 2012.

PPCB stock trades at $1.01 with a market capitalization of $883115. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.11, price-to-sales of 47.73. Over the past 52 weeks the stock has ranged between $1.01 and $270.25, and currently trades 99.6% below its 52-week high.

On profitability, PPCB generates a return on equity (ROE) of -421.43%, return on capital employed of -407.14%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides